π Partner with Pharmidex for Innovative Drug Discovery! π
August 1, 2024
Pharmidex is seeking passionate partners to discover new medicines using cutting-edge in silico strategies. Whether you're identifying protein targets for existing drugs or screening compound libraries for potential hits, we're ready to collaborate and drive groundbreaking discoveries.
Our Expertise:
· Specialist expertise in computational, structural, and molecular biology
· Gold standard software (X-Ray Crystallography, Cryo-EM, molecular docking, 3D-Pharmacopohore determination)
ο»Ώ
Harness state-of-the-art software and computational power for all steps of in silico drug discovery development. Let's innovate together!
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. π©π¬ π¨π¬ Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: β
Bitter-tasting APIs β
Unpalatable excipients β
The success of taste-masking strategies β
Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
